600201.SH
生物股份
SSE · Healthcare · Biotechnology · CN
CNY 12.43
−1.74%Year over year
Reported trailing growth
- Revenue
- +10.5%
- EBITDA
- —
- EBIT
- +9.3%
- EPS
- +30.4%
- Free cash flow
- -23.3%
- Operating cash flow
- +11.6%
Forward estimates
Based on analyst estimates
- Revenue
- +45.8%
- EBITDA
- +84.7%
- EPS
- +309.3%
Three-year CAGR
- Revenue
- -3.0%
- EBITDA
- -7.2%
- EBIT
- -25.7%
- Net income
- -22.0%
- EPS
- -22.0%
- Free cash flow
- +8.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026